A total of 20 patients were included in the safety run-in cohort and completed preliminary evaluation. Results demonstrated that Opamtistomig in combination with chemotherapy was generally well ...
The FDA has granted Orphan Drug Designation to tovecimig (CTX-009) for the treatment of patients with biliary tract cancer ...
Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today the initiation of the dose expansion phase in ...
Cell-free DNA (cfDNA) and matched tumor sample from patients with BTC were analyzed using targeted next-generation sequencing (NGS) assay and compared. We sought to define the molecular profile of ...
ctDNA is a valuable prognostic biomarker for relapse in early-stage BTC, outperforming carbohydrate antigen 19-9 levels. ctDNA monitoring can detect molecular recurrence earlier than standard ...
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary ...
In this study, researchers aimed to determine whether the addition of durvalumab to gemcitabine plus cisplatin increases time toxicity.
KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (CYCC) (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing ...
Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early ...
Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, represent a heterogeneous group of malignancies with rising global incidence and persistent dismal prognoses. Research in ...
A phase II study of pevonedistat in combination with carboplatin and paclitaxel in advanced intrahepatic cholangiocarcinoma: ECOG-ACRIN EA2187. Real-world validation of the risk estimation of tumor ...
The GAP regimen did not improve overall survival compared to GC in advanced BTCs, with similar median OS between groups. GAP treatment resulted in higher rates of severe hematologic and nonhematologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results